Targeting kidney mesangium by nanoparticles of defined size
Targeting kidney mesangium by nanoparticles of defined size
复制标题
DOI：
10.1073/pnas.1103573108
复制
发表时间：
2011-04-19
影响因子：
11.1
通讯作者：
Davis, Mark E.
中科院分区：
文献类型：
--
作者：
Choi, Chung Hang J.;Zuckerman, Jonathan E.;Davis, Mark E.
纳米粒子正在被研究用于许多医疗应用，并显示出作为一种新兴的药物输送载体的潜力。纳米粒子的物理化学性质(例如，靶向配体的大小、表面电荷、形状和密度)如何使其能够克服生物障碍并以足够的量到达指定的细胞目的地以产生生物功效，这是人们感兴趣的研究。尽管已证实纳米粒子在细胞部位积累成功，并在选定的几个器官(如肿瘤和肝脏)出现了下游治疗效应(如靶基因抑制)，但有关工程纳米粒子有效地输送到其他器官的报道仍然很少。在这里，我们展示了直径类似于75+/-25纳米的纳米颗粒靶向肾脏的系膜。这些数据显示了颗粒直径对靶向肾系膜的影响。由于许多疾病起源于肾脏的这一区域，我们的发现为构建以纳米颗粒为基础的治疗药物建立了设计标准，以针对涉及肾脏系膜的疾病。
Nanoparticles are being investigated for numerous medical applications and are showing potential as an emerging class of carriers for drug delivery. Investigations on how the physicochemical properties (e.g., size, surface charge, shape, and density of targeting ligands) of nanoparticles enable their ability to overcome biological barriers and reach designated cellular destinations in sufficient amounts to elicit biological efficacy are of interest. Despite proven success in nanoparticle accumulation at cellular locations and occurrence of downstream therapeutic effects (e.g., target gene inhibition) in a selected few organs such as tumor and liver, reports on effective delivery of engineered nanoparticles to other organs still remain scarce. Here, we show that nanoparticles of similar to 75 +/- 25-nm diameters target the mesangium of the kidney. These data show the effects of particle diameter on targeting the mesangium of the kidney. Because many diseases originate from this area of the kidney, our findings establish design criteria for constructing nanoparticle-based therapeutics for targeting diseases that involve the mesangium of the kidney.